Coeptis Therapeutics (COEP) Stock Price, News & Analysis

Company Overview

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Key Stats

• Today's Range: $9.20 to $11.79
• 50-Day Range: $2.79 to $13.20
• 52-Week Range: $2.31 to $13.70
• Volume: 129,609 shs
• Average Volume: 184,808 shs
• Market Capitalization: $36.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Coeptis Therapeutics Stock Analysis - MarketRank™

Coeptis Therapeutics scored higher than 19% of companies evaluated by MarketBeat, and ranked 913th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Coeptis Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Coeptis Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coeptis Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coeptis Therapeutics has a P/B Ratio of 23.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.83% of the float of Coeptis Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coeptis Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coeptis Therapeutics has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coeptis Therapeutics does not currently pay a dividend.

Dividend Growth

Coeptis Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.83% of the float of Coeptis Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coeptis Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coeptis Therapeutics has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

Coeptis Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Coeptis Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.88% of the stock of Coeptis Therapeutics is held by institutions.

COEP Stock Analysis - Frequently Asked Questions

How have COEP shares performed this year?

Coeptis Therapeutics' stock was trading at $5.50 at the beginning of the year. Since then, COEP stock has increased by 105.1% and is now trading at $11.28.
View the best growth stocks for 2025 here.

How were Coeptis Therapeutics' earnings last quarter?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) issued its quarterly earnings results on Friday, August, 16th. The company reported ($1.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.20.

When did Coeptis Therapeutics' stock split?

Shares of Coeptis Therapeutics reverse split before market open on Tuesday, December 31st 2024. The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Coeptis Therapeutics?

Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Coeptis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM) and PHX Minerals (PHX).

Company Calendar

• Last Earnings: 8/16/2024
• Today: 2/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COEP
• CUSIP: N/A
• CIK: 1759186
• Web: coeptispharma.com
• Phone: 724-934-6467
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,094.50%
• Return on Assets: -219.97%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 23.50

Miscellaneous

• Outstanding Shares: 3,242,000
• Free Float: 2,456,000
• Market Cap: $36.57 million
• Optionable: Not Optionable
• Beta: -0.82